Roche is extending its China deal streak with an RNA interference (RNAi) obesity pact with Rona Therapeutics, a move that adds to a wave of partnerships targeting “visceral” fat biology. The collaboration follows a particularly active period for Roche in metabolic disease licensing, highlighting investor focus on obesity therapies beyond GLP-1. While deal terms in the brief point to meaningful upfront and milestone structure, the strategic signal is clear: large pharma is continuing to buy into RNAi modalities that can drive sustained target knockdown in tissues implicated in energy storage and insulin resistance. The Rona alliance also underscores that obesity is becoming a multi-mechanism therapeutic category, with companies attempting to differentiate on durability, route of administration, and depth of tissue engagement—areas where RNAi programs have positioned themselves.